This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): vapitadine dihydrochloride
Description: Hivenyl is an oral formulation of vapitadine dihydrochloride, a novel antihistamine. This H1-receptor antagonist serves to reduce or eliminate effects mediated by histamine, an endogenous chemical mediator released during allergic reactions. In preclinical studies, Hivenyl did not cross the blood-brain barrier, which could help it avoid side effects, such as sedation.
Deal Structure: Barrier acquired a portfolio of dermatological product candidates and intellectual property from within the Johnson & Johnson family of companies. The assets were licensed, free of any royalties, from Janssen Pharmaceutica Products, L.P., Johnson & Johnson Consumer Companies, Inc. and Ortho-McNeil Pharmaceutical, Inc., each a Johnson & Johnson company, in exchange for an equity interest in Barrier. Johnson & Johnson, through any of its affiliates, also has a right of first negotiation for the commercialization of product candidates based on such intellectual property.
In June 2008, Barrier Therapeutics announced that it has signed a definitive merger agreement with Stiefel Laboratories.
In April 2009, GlaxoSmithKline and Stiefel Laboratories announced that they have signed an agreement under which GSK will acquire Stiefel in a deal valued at up to $3.6 billion. GSK's existing prescription dermatological products will be combined with Stiefel's and the new specialist global...See full deal structure in Biomedtracker
Additional information available to subscribers only: